

## Special Issue

# Inflammatory Bowel Diseases: Clinical Advances and Emerging Therapies

### Message from the Guest Editor

Inflammatory bowel disease (IBD) includes mainly ulcerative colitis and Crohn's disease, which are chronic, progressive diseases. IBD management is complicated and includes mesalazine, steroids, immunosuppressants, and many new biologic drugs, such as anti-tumor necrosis factor-alpha (TNF- $\alpha$ ) agents, anti-integrin agents, anti-interleukin (IL) 12-23 agents, and non-biologic small molecules. Optimal treatment should aim, on the one hand, at clinical remission, endoscopic and histopathologic healing, and prolonged response, and on the other hand, at side effects and complication avoidance. This Special Issue is dedicated to showcasing the latest clinical advancements in inflammatory bowel disease (IBD). We invite researchers and clinicians to submit their original research articles and reviews that contribute to the understanding, diagnosis, treatment, and management of IBD.

---

### Guest Editor

Prof. Dr. Ewa Malecka-Wojcieszko  
Department of Digestive Tract Diseases, Medical University of Lodz,  
Lodz, Poland

---

### Deadline for manuscript submissions

20 July 2026



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/223155](https://mdpi.com/si/223155)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com/)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).